Histone anti-cancer vaccines
US-2018155403-A1 · Jun 7, 2018 · US
H3.3 CTL peptides and uses thereof
US10441644B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10441644-B2 |
| Application number | US-201715613837-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 5, 2017 |
| Priority date | May 5, 2015 |
| Publication date | Oct 15, 2019 |
| Grant date | Oct 15, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A T-cell expressing one or more polypeptides comprising a T-cell receptor (TCR) or fragment thereof that binds to a peptide/major histocompatibility complex (MHC) complex, wherein the peptide in the peptide/MHC complex consists of 10-12 amino acids and comprises (R/A)MSAP(S/A)TGGV (SEQ ID NO:1). 2. The T-cell of claim 1 , wherein the TCR or fragment thereof is heterologous to the T-cell. 3. The T-cell of claim 1 , wherein expression of the TCR or fragment thereof is under the control of a heterologous promoter. 4. The T-cell of claim 1 , wherein the peptide consists of RMSAPSTGGV (SEQ ID NO:2).
Assignees
Inventors
Classifications
Vaccine for a specifically defined cancer · CPC title
from mammals · CPC title
- A61K38/03Primary
Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof · CPC title
Cytokines; Lymphokines; Interferons · CPC title
Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10441644B2 cover?
- Peptides that generate an immune response to glioma-related H3.3 proteins and methods of their use are provided.
- Who is the assignee on this patent?
- Univ California
- What technology area does this patent fall under?
- Primary CPC classification A61K38/03. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).